Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The cardiac ryanodine-receptor channel type 2 (RyR2) is a large intracellular calcium release channel predominantly expressed in cardiac muscle cells. It plays a central role in excitation-contraction coupling by mediating the release of Ca²⁺ from the sarcoplasmic reticulum (SR) into the cytosol, which is essential for cardiac muscle contraction. Dysfunction or mutations in RYR2 are linked to several cardiovascular diseases: Catecholaminergic polymorphic ventricular tachycardia (CPVT), Atrial fibrillation, and Heart failure. Abnormalities may result from altered gating properties leading to inappropriate diastolic SR Ca²⁺ leak—contributing to arrhythmogenesis and contractile dysfunctions seen in heart disease patients.
Modulation of calcium release from the sarcoplasmic reticulum
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cardiac Ryanodine-Receptor Channel Type 2 (RyR2).